{"organizations": [], "uuid": "e6ea976f9cc95a4d42bd9cc24d49ae3b5cfb6e1e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-sage-therapeutics-qtrly-net-loss-p/brief-sage-therapeutics-qtrly-net-loss-per-share-1-75-idUSASB0C6X3", "country": "US", "domain_rank": 408, "title": "BRIEF-Sage Therapeutics Qtrly Net Loss Per Share $1.75", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-22T13:58:00.000+02:00", "replies_count": 0, "uuid": "e6ea976f9cc95a4d42bd9cc24d49ae3b5cfb6e1e"}, "author": "", "url": "https://www.reuters.com/article/brief-sage-therapeutics-qtrly-net-loss-p/brief-sage-therapeutics-qtrly-net-loss-per-share-1-75-idUSASB0C6X3", "ord_in_thread": 0, "title": "BRIEF-Sage Therapeutics Qtrly Net Loss Per Share $1.75", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters staff", "sentiment": "none"}, {"name": "sage therapeutics inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 22, 2018 / 12:01 PM / Updated 8 minutes ago BRIEF-Sage Therapeutics Qtrly Net Loss Per Share $1.75 Reuters Staff Feb 22 (Reuters) - Sage Therapeutics Inc: * SAGE THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES PIPELINE UPDATE * ON TRACK TO SUBMIT NEW DRUG APPLICATION FOR BREXANOLONE FOR POSTPARTUM DEPRESSION IN 1H 2018 FOLLOWING PRE-NDA MEETING * ON TRACK TO SUBMIT NEW DRUG APPLICATION FOR BREXANOLONE FOR POSTPARTUM DEPRESSION IN 1H 2018 FOLLOWING PRE-NDA MEETING * QTRLY NET LOSS PER SHARE - BASIC AND DILUTED $1.75 * CASH, CASH EQUIVALENTS,MARKETABLE SECURITIES AS OF DEC 31, 2017 WERE $518.8 MILLION, VERSUS $397.5 MILLION AT DECEMBER 31, 2016 * EXPECTS OPERATING EXPENSES TO INCREASE YEAR OVER YEAR IN 2018 * Q4 EARNINGS PER SHARE VIEW $-1.99 -- THOMSON REUTERS I/B/E/S * SAGE -EXPECTS EXISTING CASH,CASH EQUIVALENTS, MARKETABLE SECURITIES, OTHER SALES TO ENABLE CO TO FUND OPERATING EXPENSES, CAPEX REQUIREMENTS INTO 2020 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-22T13:58:00.000+02:00", "crawled": "2018-02-22T14:15:42.000+02:00", "highlightTitle": ""}